Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CRNZA
ADC Name
ADC1-1
Synonyms
ADC1 1
   Click to Show/Hide
Organization
BeiGene Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Cofetuzumab
  Antibody Info 
Antigen Name
Inactive tyrosine-protein kinase 7 (PTK7)
  Antigen Info 
Payload Name
ADC 1-1 payload
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
ADC 1-1 linker
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Maximum inhibition efficiency (MIE) 
38.87
%
A-549 cells
Lung adenocarcinoma
Maximum inhibition efficiency (MIE) 
95.76
%
OVCAR-3 cells
Ovarian serous adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.31
nM
OVCAR-3 cells
Ovarian serous adenocarcinoma
Half Maximal Effective Concentration (EC50) 
> 200
nM
A-549 cells
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 38.87% Low PTK7 expression (PTK7 +)
Method Description
Cells were then treated with a 10-points titration of compounds, including ADC1-1, ADC1-11,ADC1-4,ADC1-2 and ADC1-12. The plates were incubated for 7 days at 37°C, 5% CO2. Next, 50 uL of Cell-Titer- Glo reagent was added to each well. The mixture was mixed on an orbitalshaker for 10 mins to allow cell lysis.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Maximum inhibition efficiency (MIE) 95.76% High PTK7 expression (PTK7 +++)
Method Description
Cells were then treated with a 10-points titration of compounds, including ADC1-1, ADC1-11,ADC1-4,ADC1-2 and ADC1-12. The plates were incubated for 7 days at 37°C, 5% CO2. Next, 50 uL of Cell-Titer- Glo reagent was added to each well. The mixture was mixed on an orbitalshaker for 10 mins to allow cell lysis.
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.31 nM High PTK7 expression (PTK7 +++)
Method Description
Cells were then treated with a 10-points titration of compounds, including ADC1-1, ADC1-11,ADC1-4,ADC1-2 and ADC1-12. The plates were incubated for 7 days at 37°C, 5% CO2. Next, 50 uL of Cell-Titer- Glo reagent was added to each well. The mixture was mixed on an orbitalshaker for 10 mins to allow cell lysis.
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 200 nM Low PTK7 expression (PTK7 +)
Method Description
Cells were then treated with a 10-points titration of compounds, including ADC1-1, ADC1-11,ADC1-4,ADC1-2 and ADC1-12. The plates were incubated for 7 days at 37°C, 5% CO2. Next, 50 uL of Cell-Titer- Glo reagent was added to each well. The mixture was mixed on an orbitalshaker for 10 mins to allow cell lysis.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
References
Ref 1 Antibody drug conjugates; 2023-07-06.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.